Tutors

PLG MSc Tutors

IAN SCOULAR

Ian has served as Director of Business Development for Protherics PLC since July 2002. Ian has more than 20 years business development, experience in the pharmaceutical industry through positions in Nycomed Pharma, Schering Plough and Reckitt & Colman. He is responsible for seeking commercial partners for the Company’s development products and intellectual property portfolio, and in-licensing new products. More recently, he played a major part in negotiations with AstraZeneca, leading to the licensing agreement with Protherics in December 2005. This deal was recognised at the 2006 Scrip Awards as 'Licensing Deal of the Year'.

SHARON FINCH

Sharon Finch is the CEO of Medius Associates, a specialised pharma business development consultancy group. Sharon has more than 30 years proven experience in business development having worked in-house at the Wellcome Foundation, Medeva plc and Ono Pharmaceutical Co. Ltd. prior to founding Medius in 1994.
Sharon is Editor of the Business Development & Licensing Journal and the Course Director for the MSc in Pharmaceutical Business Development and Licensing run at the University of Manchester. She is also a past Chairman of the UK Pharmaceutical Licensing Group Ltd, a past President of the European PLG Council and a member of the LES Healthcare Committee in the UK.

ALAN WARRANDER

Alan Warrander has over 25 years wide-ranging experience in the Pharmaceutical Industry having worked both in Pharma companies and as a Consultant.
Until the end of 2007, Alan was Senior Vice President, Life Sciences at Wood Mackenzie, the global consultancy firm where he provided consultancy advice and expert scientific opinion to Pharma, Biotech companies, Finance groups and Law firms primarily in the areas of Partnering, Due Diligence and Strategic Planning. Alan was also responsible for the production of a number of Expert Reports on a range of companies in support of potential AIM flotations.
His academic background is in Xenobiotic Metabolism, with a PhD from Birmingham University and a BSc in Chemistry and Biochemistry from St Andrews. He is a recognised conference speaker having being invited to present on various aspects of Partnering and Due Diligence.

ROGER DAVIES

Roger Davies works as a consultant in pharmaceutical licensing and business development. Having personally completed over 80 deals he specialises in valuations, deal structuring and negotiating licensing and acquisition deals. He is a former Chairman of the UK Pharmaceutical Licensing Group, the professional association of licensing and business development executives and is the Finance module leader for the Business Development MSc at the University of Manchester.
He was formerly the Group Director of Licensing and Business Development at Bioglan Pharma Plc where he was responsible for the global licensing and acquisition of products and drug delivery technologies as well as European distributors and the Legal department. Prior to joining Bioglan in 2000, Roger was employed at Mundipharma International for 10 years as Director of International Business Development where he was responsible for product and company acquisitions/disposals, inward and outward product licensing and European pricing.
Roger has a Masters degree in Economics.

MIKE HERMAN

Mike Herman is a consultant on Accounting and Finance. His current responsibility are : Post graduate diploma and MBA workshops, In-company training courses as consultant for RDI Ltd., Coventry.

History:

University of Northampton:

1978 - Senior Lecturer in Accounting and Finance.
Principal Lecturer, Field Chair Accounting and Finance, Head of Division of Accounting and Finance.
2005 - Acting Head of School, School of Accounting, Information Systems and Law
September 2002 – 2005 - Senior Lecturer in Accounting and Finance (fractional post).

Other teaching experience:

August 1991 - Nov 1993. - Leicester University MBA workshops (Distance Learning – delivered in UK and Far East)
2003 and 2004 Leicester University Medici project (Business planning for post-doctoral innovation – including development of a business planning spreadsheet model)
2003 Leicester University, Msc in Marketing - delivery
2002 – 2004 Leicester University, Management Accounting at undergraduate levels 1 and 3 delivery of course including maintaining web page and all materials for the courses
2002 – 2003 Coventry University, MBA Programme – delivery

STEPHEN REESE

Stephen is a Partner in Olswang's Intellectual Property Group and leads its Life Sciences practice.
Stephen advises clients on both contentious and non-contentious intellectual property matters including patents, trade marks, trade secrets and copyright. He represents and advises a broad range of clients in relation to the protection, exploitation and enforcement of their intellectual property rights.
He has significant experience representing those clients within the life sciences and technology fields on both contentious and non-contentious matters. Stephen has represented clients in significant patent litigation disputes including Boston Scientific and Lonza Biologics. He also has considerable experience in commercial transactions within the life sciences industry. He advises on research & development, licensing, disposals, acquisitions and due diligence activities and has acted on behalf of clients in highly successful and publicised collaboration transactions. In connection with his life sciences practice Stephen also advises clients on UK and EU regulatory matters.
Stephen is recognised for his expertise and has been described by Legal 500 as "astute" and "highly knowledgeable". Stephen is currently an examiner for one of the papers for CIPA (Patent Attorneys) and ITMA (Trade Mark Attorneys) students and has given many external lectures on topics including IP audits, co-marketing and co-promotion agreements, research and development contracts and injunctions. He is also a tutor on the PLG's Masters degree.

PAUL RANSON

Paul spent the early part of his career as an in-house lawyer for Smith Kline and Merck Sharpe & Dohme. He is a specialist in the commercial business development and regulatory aspects of the above industries.
He has written and lectured extensively in legal issues for the sector including on licensing and outsourcing within the field. His publications include six report-length papers for the FT, Bridgehead and Legalease.
He is also Head of the Editorial Board of Health Science Law and Business (Legalease). He is on the Legal Issues Committee of the ABHI and has been a member of a local 7 Ethics Committee for five years

ANDREW GOTTSCHALK

Andrew Gottschalk has acted as a consultant on negotiation problems for many major international corporations and non-profit organisations.
After "sharp end" experience as a commercial and industrial relations negotiator in the motor vehicle and electronics industries Andrew spent twelve years on the faculty of the London Business School working exclusively on negotiating issues. His pioneering research work on social psychological factors in negotiating became the basis for educational innovation and thought leadership at the School. Between 1983 and 1986 he was also a director of a venture capital company that invested in start-up situations.
A bilingual psychologist, Andrew has written extensively on negotiating. He has held visiting professorships Argentina, France, Germany, Japan and the Netherlands.
In 1993, he established Group AG to take this his work further within a broader European context. Group AG is a "one stop shop on negotiating". It undertakes negotiating assignments consulting on negotiating strategy, tactics and processes and develops individual, group and organisational negotiating competencies. A significant element of this work is based on the Woodstock Negotiating Style Inventory, that he developed to facilitate one-to-one mentoring and robust individual learning.

JOHN ANSELL

Since 1989 John Ansell has been a pharmaceutical industry consultant based in Thame, near Oxford, UK. He concentrates on international projects with a commercial and strategic emphasis, reflecting his previous industry experience. A biochemistry graduate with an MA in business studies, John Ansell’s 20-year career in the UK and Holland included positions with Organon, Schering AG, Fisons, Solvay and Glaxo Holdings.
Subsequently, as an independent industry consultant based in Thame, near Oxford, UK, John has worked for more than 110 clients on commercial strategic projects. Over the past year he has advised six of the top seven global investment banks; recently he been placed in the top 5% Leader category of the Gerson Lehrman Group’s consultants based on quality of interaction with its clients.
John is a frequent speaker including at IPLS conferences in Tokyo, Venice and Geneva. He has also acted as chairman at over 30 industry conferences. John is the author of over 40 articles and reports on strategic industry issues.
John was a long-standing member of the Editorial Advisory Board of the US journal Pharmaceutical Executive (1990-2002), and has been Chairman of the Advisory Board of Decision Resources since its inception in 2005. He is also Honorary Consultant to the University of Manchester School of Pharmacy and Pharmaceutical Sciences.

PETER COZENS

TIM SAMPSON

Tim qualified as a Barrister in 2000 and his practice now covers all aspects of UK and European intellectual property law, competition law, biotech commercialisation and bio-regulatory matters, as well as more general commercial litigation. His experience includes dealing with matters before the High Court, the Technology and Construction Court and the Court of Appeal in the UK, as well as the European Patent Office and OHIM.
Prior to becoming a barrister Tim took a B.Sc.(Hons) in Molecular Biology & Biochemistry, at Durham University and a Ph.D. in Biochemistry at the University of Cambridge; where he carried out research into the insect receptor proteins for Bacillus thuringiensis delta-endotoxins.